Heterogeneity of MET pathway activation in osimertinib-resistant EGFR-mutant NSCLC, as we previously have shown (10), may also be an important factor in assessing response to osimertinib and savolitinib combination. This evidence concerns the gene MET and non-small cell lung carcinoma.